![](https://news.europawire.eu/wp-content/uploads/2022/01/Bayer_Cross_1-144x144.jpg)
Agreement strengthens Bayer’s new cell and gene therapy platform further / Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems / Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more … Read the full press release